Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer

Dobrowsky, W.; Naudé, Jonathan; Widder, Joachim; Dobrowsky, E.; Millesi, W.; Pavelka, R; Grasl, Caterina M.; Reichel, Michaela

doi:10.1016/s0360-3016(98)00321-6

Cited by 44 publications

(13 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A significantly better loco-regional control rate than in the control group was also seen with the 5-nitroimidazole-based radiosensitizer nimorazole (25,26). In addition, several clinical trials have demonstrated the benefit of the bioreductive alkylating agent, mitomycin C, as an adjunct to radiotherapy (7), continuous hyperfractionated accelerated radiotherapy (27), or radiochemotherapy (28) in the management of head and neck cancer. Finally, clinical studies confirm the usefulness of the bioreductive agent tirapazamine as an adjunct to radiotherapy (8) or radiochemotherapy in patients with advanced head and neck cancers (29).…”

Section: Discussionmentioning

confidence: 95%

Advantage of Combining NLCQ-1 (NSC 709257) with Radiation in Treatment of Human Head and Neck Xenografts

et al. 2007

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 95%

Advantage of Combining NLCQ-1 (NSC 709257) with Radiation in Treatment of Human Head and Neck Xenografts

et al. 2007

View full text Add to dashboard Cite

“…Future research is required to investigate the longer term outcomes including late toxicity with comparison to the standard treatment (i.e. concurrent chemo-radiotherapy) [18][19][20][21][22][23][24][25][26][27][28][29][30][31]. …”

Section: Discussionmentioning

confidence: 99%

Accelerated Fractionation Radiotherapy in Treating Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma

Sakr¹

2017

JCPCR

View full text Add to dashboard Cite

Purpose: Acute toxicity, tumor control and survival outcomes were prospectively evaluated following accelerated fractionation radiotherapy for head and neck squamous cell carcinoma (HNSCC).Methods: Between 2012-2013, patients with non-metastatic HNSCC (T1-2N1 or T3-4N0-1) were accrued to a phase I/II prospective study. All patients were treated with 70 Gy in 30 fractions over 5 weeks (6 fractions/week). Acute toxicity, clinical response, local (LC), regional (RC) and distant control (DC), disease free-(DFS) and overall-survival (OS) were analyzed. Results:In total, 40 patients were enrolled; median follow-up was 41 months. The majority of patients were clinical stage III (n=37, 92.5%), ≥ 50 year (n=34, 85%), and male gender (n=29, 72.5%). Approximately half of the patients had laryngeal cancer. The overall grade 3 acute toxicity was 62.5%; mainly mucositis (n=23, 57.5%) and dysphagia (n=18, 45%). Overall, 34 patients (85%) showed complete response following radiotherapy. Three-year LC, RC, DC, OS and DFS were 81.6%, 85.3%, 90.3%, 64.4% and 58.7%, respectively. Conclusion:Our proposed accelerated fractionation radiotherapy regimen appears feasible and safe. Future research is required to investigate the longer term outcomes including late toxicity with comparison to the standard treatment (i.e. concurrent chemo-radiotherapy).

show abstract

“…Despite more than 70 randomized trials, the effect of chemotherapy on nonmetastatic head and neck squamous cell carcinoma remains uncertain. However, concurrent chemotherapy and radiation has been a more consistently successful treatment, and a survival benefit from the addition of such single agents as fluorouracil [10,11,12], bleomycin [13], mitomycin C [14] and cisplatin [15, 16] has been observed. …”

Section: Discussionmentioning

confidence: 99%

A Phase I Study of Concurrent Chemoradiotherapy with S-1 for T2N0 Glottic Carcinoma

Tsuji

Kiba²,

Nagata³

et al. 2006

Oncology

View full text Add to dashboard Cite

Objective: Chemoradiation based on S-1, a novel oral antitumor agent of fluorinated pyrimidines, is the treatment for T2N0 glottic carcinoma; however, the optimal scheduling and dosing have still not been established. A phase I study was conducted to determine the maximum tolerated dose of S-1 with radiotherapy of 2 Gy/day for 5 days a week to a total dose of 60 Gy. Endpoints of this study were to examine the toxicity profile of this regimen and to determine the recommended dose of S-1. Methods: Concomitant administration with the above-mentioned radiotherapy of S-1 once a day for 2 weeks, beginning on the day therapy was started, followed by 2 weeks off the drug and 2 weeks on the drug with the dose escalating from S-1 60 mg/body (level 1) to 80 mg/body/day (level 2), and then to 100 mg/body/day (level 3). Results: Twenty-one patients were valid for safety. Eighteen patients were enrolled in the dose-escalation phase. In all patients, S-1 was administered. The maximum tolerated dose was determined to be 100 mg/body/day and the dose-limiting toxicity was indicated by the onset of grade 3 chemoradiation dermatitis. Therefore, the determined recommended dose of S-1 was 80 mg/body/day. Objective response according to Response Evaluation Criteria in Solid Tumors were observed in 20 of 21 patients who had measurable disease (95.2%). Conclusion: Concurrent S-1 and radiotherapy was feasible and well tolerated, and was suggested to produce a worthwhile response in T2N0 glottic carcinoma. These results warrant further investigation, and a phase II has already been started.

show abstract

Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer

Cited by 44 publications

References 11 publications

Advantage of Combining NLCQ-1 (NSC 709257) with Radiation in Treatment of Human Head and Neck Xenografts

Advantage of Combining NLCQ-1 (NSC 709257) with Radiation in Treatment of Human Head and Neck Xenografts

Accelerated Fractionation Radiotherapy in Treating Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma

A Phase I Study of Concurrent Chemoradiotherapy with S-1 for T2N0 Glottic Carcinoma

Contact Info

Product

Resources

About